AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02871167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Description: After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation.
Study NCT02871167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte/embryo freezing
Description: Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
Study NCT00966147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing oxygen delivery .
Description: The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
Study NCT00076310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m\^2 IV repeated every 21 days.
Study NCT00076310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
Study NCT00076310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 IV every 21 days.
Study NCT02609984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMB305
Description: A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
Study NCT02609984 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: atezolizumab
Description: IV Infusion
Study NCT02609984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: IV Infusion
Study NCT00398047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitadine and Hematopoietic Growth Factors
Description: Combination of Azacitadine and Hematopoietic Growth Factors
Study NCT04816123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Donafenib
Description: Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
Study NCT00161265 — intervention group
Intervention type: PROCEDURE
Intervention: tissue procurement
Description: tissue procurement
Study NCT04074057 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Cardiac Rehab Classes
Description: conventional weekly CR programme lasting 8-12 sessions.
Study NCT04074057 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Heart Track
Description: Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness.
Study NCT03092817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
Study NCT03998371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low-coverage whole-genome sequencing of urine exfoliated cells
Description: The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
Study NCT03092817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose
Study NCT00788242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium
Description: 20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Study NCT00788242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine10mg
Description: Amlodipine 10mg
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine10mg
Description: Amlodipine 10mg
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study NCT03889145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study NCT03454477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional open surgery
Description: conventional open surgery
Study NCT03454477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic thyroidectomy
Description: endoscopic thyroidectomy
Study NCT03454477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic thyroidectomy
Description: robotic thyroidectomy
Study NCT04017117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh
Description: comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
Study NCT04017117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh
Description: comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
Study NCT04588766 — intervention group
Intervention type: OTHER
Intervention: constipation group
Description: Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
Study NCT04588766 — intervention group
Intervention type: OTHER
Intervention: control group
Description: Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
Study NCT05371106 — intervention group
Intervention type: OTHER
Intervention: exposure to mycotoxins
Description: self-report eating questionnaire
Study NCT02570997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
Study NCT02570997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered.
Study NCT02646956 — intervention group
Intervention type: OTHER
Intervention: sweeteners
Description: Participants tasted a variety of nutritive and nonnutritive sweeteners
Study NCT06248437 — intervention group
Intervention type: OTHER
Intervention: innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage
Description: All participants completed a survey on sociodemographic data (age, sex, respiratory problems, smoking, among others). Weight, height, skin folds, and a blood sample were taken to quantify the Oxygen Radical Absorption Capacity (ORAC) units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and lipid profile. At that time, they were explained how they should eat the nutraceutical food, starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant
Study NCT00998842 — intervention group
Intervention type: DEVICE
Intervention: Recom Model 100
Description: Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
Study NCT00998842 — intervention group
Intervention type: DEVICE
Intervention: GE 5000 ECG Monitor System
Description: Wired ECG system
Study NCT04478253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HypnoVR
Description: Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally
Study NCT00023998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo resection
Study NCT00023998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT01456143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Microendoscopy (HRME)
Description: High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
Study NCT01456143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proflavine hemisulfate
Description: 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
Study NCT00926432 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EOS™ Acquisition
Description: Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
Study NCT03964259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: Administration of post HDMTX intravenous fluids (IVF)
Study NCT03964259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluids
Description: Administration of post HDMTX intravenous fluids (IVF)
Study NCT00986323 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature controlled Laminar Airflow (TLA)
Description: Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
Study NCT00986323 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TLA
Description: Placebo TLA (without filtration and TLA function)
Study NCT01249586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-learning
Description: A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece
Description: The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask
Description: The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
Study NCT03260764 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: long term Bifocal Spectacles
Description: wearing Bifocal Spectacles for one year
Study NCT03038113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7062931
Description: Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
Study NCT03038113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
Study NCT03038113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Modulator
Description: Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
Study NCT00990613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon IR
Description: A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
Study NCT00990613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Study NCT00990613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Study NCT00990613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dimebon Transdermal
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Study NCT00023998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00023998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01144377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546
Description: Administered subcutaneously
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
Study NCT04032834 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
Study NCT01144377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously
Study NCT01144377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADO09 formulation
Description: Subcutaneous injection of ADO09 formulation
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous injection of 0.9% NaCl
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 0.9% NaCl
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symlin®
Description: Subcutaneous injection of pramlintide
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin®
Description: Subcutaneous injection of human insulin
Study NCT03916640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: Subcutaneous injection of insulin lispro
Study NCT03472989 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave
Description: Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.
Study NCT03472989 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-radial extracorporeal shock wave
Description: Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.
Study NCT03472989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized high-load exercise program
Description: Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis.
Study NCT03472989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
Study NCT04566913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pontic Shield Technique
Description: • Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
Study NCT01885689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT01885689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT01885689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant
Study NCT01885689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or PO
Study NCT01885689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT01885689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies